Literature DB >> 1431577

Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids.

H Gylling1, G L Vega, S M Grundy.   

Abstract

Low plasma concentrations of high density lipoprotein (HDL) cholesterol and apolipoprotein A-I (apoA-I) are major risk factors for coronary heart disease (CHD). Low HDL levels are common in patients with hypertriglyceridemia, but they also occur in those with normal plasma lipids; the latter include obese patients and cigarette smokers, though other patients with low HDL levels are neither obese nor smokers. The present study was designed to define metabolic causes of low apoA-I levels in normal-weight, normolipidemic patients. ApoA-I tracer studies were carried out in two groups of normolipidemic patients having low HDL levels to determine input rates and residence times for ApoA-I; these patients included 11 nonobese nonsmokers and 11 nonobese cigarette smokers. Their results were compared to those of 20 normal-weight, normolipidemic controls with normal HDL levels and 12 obese nonsmokers also having low HDL. In all three groups manifesting low HDL-cholesterol and low apoA-I levels, residence times for plasma apoA-I were reduced by approximately 30%, compared to control subjects with normal HDL levels. In contrast, average input rates for apoA-I were similar among the three low-HDL patients and control subjects. No differences in apoA-I kinetics were observed among any of the three groups with low apoA-I concentrations. Within each of the four groups of the study, however, input rates for apoA-I were highly correlated with plasma concentrations of apoA-I. Thus, for individuals with normal levels of plasma lipids, both residence times and input rates for apoA-I appeared to be important determinants of apoA-I levels. Residence times for apoA-I were reduced in almost all patients with low apoA-I levels, regardless of concomitant factors, whereas input rates were highly variable among individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1431577

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels.

Authors:  J C Cohen; Z Wang; S M Grundy; M R Stoesz; R Guerra
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

Review 2.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

3.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

4.  Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.

Authors:  Frank M Sacks; Lawrence L Rudel; Adam Conner; Hassibullah Akeefe; Gerhard Kostner; Talal Baki; George Rothblat; Margarita de la Llera-Moya; Bela Asztalos; Timothy Perlman; Chunyu Zheng; Petar Alaupovic; Jo-Ann B Maltais; H Bryan Brewer
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

5.  Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM.

Authors:  C M Forsblom; J G Eriksson; A V Ekstrand; A M Teppo; M R Taskinen; L C Groop
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

Review 6.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

7.  Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in Humans.

Authors:  Carlos O Mendivil; Jeremy Furtado; Allyson M Morton; Liyun Wang; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-11-05       Impact factor: 8.311

8.  Unacylated Ghrelin is associated with the isolated low HDL-cholesterol obese phenotype independently of insulin resistance and CRP level.

Authors:  Juan-Patricio Nogueira; Marie Maraninchi; Sophie Béliard; Anne Marie Lorec; Bruno Berthet; Audrey Bégu-Le Corroller; Noémie Dubois; Rachel Grangeot; Catherine Mattei; Jean Gaudart; Alain Nicolay; Henri Portugal; Bernard Vialettes; René Valéro
Journal:  Nutr Metab (Lond)       Date:  2012-03-13       Impact factor: 4.169

9.  Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations.

Authors:  H N Ginsberg; C Ngai; X J Wang; R Ramakrishnan
Journal:  Arterioscler Thromb       Date:  1993-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.